For central nervous system (CNS) applications, attempts are being made to deliver AAV gene therapy directly to the brain parenchyma or the cerebrospinal fluid (CSF) space by intra-cisterna magna ...

AAV vectors are used clinically to treat a number of rare inherited retina diseases, but also carry the risk of eliciting sight threatening ocular inflammation. Establishing how AAV-mediated ...

Somatic gene transfer with vectors such as adeno-associated virus (AAV) can overcome these limitations. ReGenX's AAV Vector Technology gives extremely efficient and stable gene expression in ...

AAV = Adeno-associated virus ... through their innate ability to home to areas of inflammation. Restoration of the balance between proinflammatory and immunosuppressant cytokines through gene ...

AAV = Adeno-associated virus ... through their innate ability to home to areas of inflammation. Restoration of the balance between proinflammatory and immunosuppressant cytokines through gene ...

NGN-401 uses the AAV9 viral vector for delivery. High doses of AAV are associated with inflammation and excessive activity of the complement system, a part of the immune system. The complication ...

adeno-associated virus (AAV), to deliver the gene for a specific enzyme into cells. The new gene therapy automatically ...

Existing gene therapies have primarily used a small number of naturally occurring AAV vectors limited by low delivery efficiency as well as problems with pre-existing immunity and manufacturability.

Some research has suggested systemic administration of AAV vectors can cause damage to liver cells and inflammation. Dyno's AAV platform, called CapsidMap, uses artificial intelligence to improve ...

The results underscore the potential of KRIYA-497, an investigational, intramuscularly-administered AAV gene therapy designed to express native fibroblast growth ... MASH is a condition in which ...